Last 12 months
Inside the activity.
2 purchase rows · 107 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 11 |
| Dec 2025 | 0 | 5 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 2 | 3 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 5 |
| Jun 2026 | 0 | 12 |
| Jul 2026 | 0 | 26 |
| Aug 2026 | 0 | 18 |
| Sep 2026 | 0 | 15 |
| Oct 2026 | 0 | 9 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 28, 2022 Filed Sep 30, 2022 20:30 UTC |
Hunt HazelChief Scientific Officer
|
Tax withholdingCommon Stock | 29,997 | $26.04 | $781,121.88 |
DisclosureSEC source: 0000899243-22-032305 · doc4.xml · nonDerivative · entry 2 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,146 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and the withholding of taxes arising from a net (cashless) exercise of stock options. The options subject to the net exercise were to expire on January 30, 2023. Read SEC document |
| September 28, 2022 Filed Sep 30, 2022 20:30 UTC |
Hunt HazelChief Scientific Officer
|
Exercise / conversionCommon Stock | 50,000 | $2.08 | $104,000.00 |
DisclosureSEC source: 0000899243-22-032305 · doc4.xml · nonDerivative · entry 1 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2022 Filed Sep 8, 2022 21:15 UTC |
Robb Gary CharlesChief Business Officer
|
SaleCommon Stock | 50,000 | $26.06 | $1,303,000.00 |
DisclosureSEC source: 0000899243-22-030683 · doc4.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,544 F1 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $25.72 to $26.39. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. F2 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 01, 2022 Filed Sep 7, 2022 00:59 UTC |
Robb Gary CharlesChief Business Officer
|
GrantCommon Stock | 1,010 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-030517 · doc4.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,544 F3 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements under the Purchase Plan. Read SEC document |
| September 01, 2022 Filed Sep 7, 2022 00:59 UTC |
Robb Gary CharlesChief Business Officer
|
GrantCommon Stock | 1,010 | $25.98 | $26,239.80 |
DisclosureSEC source: 0000899243-22-030517 · doc4.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,534 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on September 1, 2022. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. Read SEC document |
| September 01, 2022 Filed Sep 7, 2022 00:50 UTC |
Maduck SeanSee Remarks
|
Exercise / conversionStock option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000899243-22-030515 · doc4.xml · derivative · entry 7 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,602 Underlying: Common Stock · 15,000 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully exercisable. Read SEC document |
| September 01, 2022 Filed Sep 7, 2022 00:50 UTC |
Maduck SeanSee Remarks
|
GrantCommon Stock | 922 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-030515 · doc4.xml · nonDerivative · entry 4 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,462 F5 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements under the Purchase Plan. Read SEC document |
| September 01, 2022 Filed Sep 7, 2022 00:50 UTC |
Maduck SeanSee Remarks
|
GrantCommon Stock | 922 | $25.98 | $23,953.56 |
DisclosureSEC source: 0000899243-22-030515 · doc4.xml · nonDerivative · entry 3 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,540 F3 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on September 1, 2022. F4 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. Read SEC document |
| September 01, 2022 Filed Sep 7, 2022 00:50 UTC |
Maduck SeanSee Remarks
|
SaleCommon Stock | 25,000 | $25.84 | $646,000.00 |
DisclosureSEC source: 0000899243-22-030515 · doc4.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,618 F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $25.82 to $25.94. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| September 01, 2022 Filed Sep 7, 2022 00:50 UTC |
Maduck SeanSee Remarks
|
Exercise / conversionCommon Stock | 25,000 | $3.29 | $82,250.00 |
DisclosureSEC source: 0000899243-22-030515 · doc4.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2022 Filed Sep 7, 2022 00:50 UTC |
Mokari AtabakChief Financial Officer
|
GrantCommon Stock | 793 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-030514 · doc4.xml · nonDerivative · entry 2 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,586 F3 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements under the Purchase Plan. Read SEC document |
| September 01, 2022 Filed Sep 7, 2022 00:50 UTC |
Mokari AtabakChief Financial Officer
|
GrantCommon Stock | 793 | $25.98 | $20,602.14 |
DisclosureSEC source: 0000899243-22-030514 · doc4.xml · nonDerivative · entry 1 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 793 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on September 1, 2022. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. Read SEC document |
| September 01, 2022 Filed Sep 7, 2022 00:50 UTC |
Guyer WilliamChief Development Officer
|
GrantCommon Stock | 922 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-030513 · doc4.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,844 F3 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements under the Purchase Plan. Read SEC document |
| September 01, 2022 Filed Sep 7, 2022 00:50 UTC |
Guyer WilliamChief Development Officer
|
GrantCommon Stock | 922 | $25.98 | $23,953.56 |
DisclosureSEC source: 0000899243-22-030513 · doc4.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 922 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on September 1, 2022. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. Read SEC document |
| September 01, 2022 Filed Jun 3, 2025 00:57 UTC |
Maduck SeanSee Remarks
|
OtherCommon Stock | 922 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 10 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 55,516 F2 · kind: Transfer of shares without consideration to the Sean and Molly Maduck Living Trust. F3 · ownership.nature: Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. Read SEC document |
| September 01, 2022 Filed Jun 3, 2025 00:57 UTC |
Maduck SeanSee Remarks
|
GiftCommon Stock | 922 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 9 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,106 F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| August 30, 2022 Filed Sep 1, 2022 21:45 UTC |
Robb Gary CharlesChief Business Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 167,323 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-22-030201 · doc4.xml · derivative · entry 6 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 167,323 shares Expires 2023-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 30, 2022 Filed Sep 1, 2022 21:45 UTC |
Robb Gary CharlesChief Business Officer
|
Tax withholdingCommon Stock | 93,922 | $26.14 | $2,455,121.08 |
DisclosureSEC source: 0000899243-22-030201 · doc4.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,524 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and tax liability arising from a net (cashless) exercise of stock options that occurred on August 30, 2022. The options subject to the net exercise were to expire on January 30, 2023. Read SEC document |
| August 30, 2022 Filed Sep 1, 2022 21:45 UTC |
Robb Gary CharlesChief Business Officer
|
Exercise / conversionCommon Stock | 167,323 | $2.08 | $348,031.84 |
DisclosureSEC source: 0000899243-22-030201 · doc4.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,446 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2022 Filed Aug 22, 2022 23:32 UTC |
Maduck SeanSee Remarks
|
Exercise / conversionStock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0000899243-22-029492 · doc4.xml · derivative · entry 5 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2022-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 19, 2022 Filed Aug 22, 2022 23:32 UTC |
Maduck SeanSee Remarks
|
Tax withholdingCommon Stock | 406 | $27.60 | $11,205.60 |
DisclosureSEC source: 0000899243-22-029492 · doc4.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,618 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price arising from a net (cashless) exercise of stock options that occurred on August 19, 2022. The options subject to the net exercise were to expire on November 1, 2022. Read SEC document |
| August 19, 2022 Filed Aug 22, 2022 23:32 UTC |
Maduck SeanSee Remarks
|
Exercise / conversionCommon Stock | 15,000 | $2.24 | $33,600.00 |
DisclosureSEC source: 0000899243-22-029492 · doc4.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2022 Filed Jun 3, 2025 00:57 UTC |
Maduck SeanSee Remarks
|
OtherCommon Stock | 14,594 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 8 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 54,594 F2 · kind: Transfer of shares without consideration to the Sean and Molly Maduck Living Trust. F3 · ownership.nature: Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. Read SEC document |
| August 19, 2022 Filed Jun 3, 2025 00:57 UTC |
Maduck SeanSee Remarks
|
GiftCommon Stock | 14,594 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 7 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,028 F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 21:15 UTC |
Maduck SeanSee Remarks
|
Exercise / conversionStock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000899243-22-028828 · doc4.xml · derivative · entry 7 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,059 Underlying: Common Stock · 15,000 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 21:15 UTC |
Maduck SeanSee Remarks
|
Exercise / conversionStock option (right to buy) · Derivative | 9,800 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0000899243-22-028828 · doc4.xml · derivative · entry 6 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 9,800 shares Expires 2023-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 21:15 UTC |
Maduck SeanSee Remarks
|
Exercise / conversionCommon Stock | 24,800 | $28.70 | $711,760.00 |
DisclosureSEC source: 0000899243-22-028828 · doc4.xml · nonDerivative · entry 3 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $28.70 to $28.76. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 21:15 UTC |
Maduck SeanSee Remarks
|
Exercise / conversionCommon Stock | 15,000 | $3.29 | $49,350.00 |
DisclosureSEC source: 0000899243-22-028828 · doc4.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 21:15 UTC |
Maduck SeanSee Remarks
|
Exercise / conversionCommon Stock | 9,800 | $1.92 | $18,816.00 |
DisclosureSEC source: 0000899243-22-028828 · doc4.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. Read SEC document |
| August 09, 2022 Filed Aug 11, 2022 21:15 UTC |
Maduck SeanSee Remarks
|
Exercise / conversionStock option (right to buy) · Derivative | 200 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0000899243-22-028396 · doc4.xml · derivative · entry 5 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,800 Underlying: Common Stock · 200 shares Expires 2023-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 09, 2022 Filed Aug 11, 2022 21:15 UTC |
Maduck SeanSee Remarks
|
SaleCommon Stock | 200 | $28.70 | $5,740.00 |
DisclosureSEC source: 0000899243-22-028396 · doc4.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,024 F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. Read SEC document |
| August 09, 2022 Filed Aug 11, 2022 21:15 UTC |
Maduck SeanSee Remarks
|
Exercise / conversionCommon Stock | 200 | $1.92 | $384.00 |
DisclosureSEC source: 0000899243-22-028396 · doc4.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. Read SEC document |
| August 08, 2022 Filed Aug 9, 2022 22:30 UTC |
Swisher Daniel N JRDirector
|
Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0000899243-22-028147 · doc4.xml · derivative · entry 4 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 20,000 shares Expires 2025-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 08, 2022 Filed Aug 9, 2022 22:30 UTC |
Swisher Daniel N JRDirector
|
SaleCommon Stock | 15,385 | $28.32 | $435,703.20 |
DisclosureSEC source: 0000899243-22-028147 · doc4.xml · nonDerivative · entry 3 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $28.30 to $28.38 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from Issuer upon request. Read SEC document |
| August 08, 2022 Filed Aug 9, 2022 22:30 UTC |
Swisher Daniel N JRDirector
|
Tax withholdingCommon Stock | 4,615 | $28.39 | $131,019.85 |
DisclosureSEC source: 0000899243-22-028147 · doc4.xml · nonDerivative · entry 2 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,385 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price arising from a net (cashless) exercise of stock options that occurred on August 8, 2022. The options subject to the net exercise were to expire on June 18, 2025. Read SEC document |
| August 08, 2022 Filed Aug 9, 2022 22:30 UTC |
Swisher Daniel N JRDirector
|
Exercise / conversionCommon Stock | 20,000 | $6.55 | $131,000.00 |
DisclosureSEC source: 0000899243-22-028147 · doc4.xml · nonDerivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 18, 2022 Filed Jul 20, 2022 00:30 UTC |
Maduck SeanSee Remarks
|
Exercise / conversionStock option (right to buy) · Derivative | 5,000 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0000899243-22-026384 · doc4.xml · derivative · entry 7 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 5,000 shares Expires 2023-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 18, 2022 Filed Jul 20, 2022 00:30 UTC |
Maduck SeanSee Remarks
|
Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-22-026384 · doc4.xml · derivative · entry 6 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2023-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 18, 2022 Filed Jul 20, 2022 00:30 UTC |
Maduck SeanSee Remarks
|
SaleCommon Stock | 25,000 | $27.37 | $684,250.00 |
DisclosureSEC source: 0000899243-22-026384 · doc4.xml · nonDerivative · entry 3 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,024 F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $27.24 to $27.51. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| July 18, 2022 Filed Jul 20, 2022 00:30 UTC |
Maduck SeanSee Remarks
|
Exercise / conversionCommon Stock | 5,000 | $1.92 | $9,600.00 |
DisclosureSEC source: 0000899243-22-026384 · doc4.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. Read SEC document |
| July 18, 2022 Filed Jul 20, 2022 00:30 UTC |
Maduck SeanSee Remarks
|
Exercise / conversionCommon Stock | 20,000 | $2.08 | $41,600.00 |
DisclosureSEC source: 0000899243-22-026384 · doc4.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 21:20 UTC |
BELANOFF JOSEPH KChief Executive Officer
|
SaleCommon Stock | 55,111 | $26.26 | $1,446,944.82 |
DisclosureSEC source: 0000899243-22-025827 · doc4.xml · nonDerivative · entry 4 BELANOFF JOSEPH K · CIK 0001286199 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 01/29/02 Disclosed balance after: 2,483,107 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2022, as amended. F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $26.21 to $26.41. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. F5 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 01/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 21:20 UTC |
BELANOFF JOSEPH KChief Executive Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 800,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-22-025827 · doc4.xml · derivative · entry 5 BELANOFF JOSEPH K · CIK 0001286199 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 800,000 shares Expires 2023-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 21:20 UTC |
BELANOFF JOSEPH KChief Executive Officer
|
SaleCommon Stock | 279,908 | $26.27 | $7,352,007.55 |
DisclosureSEC source: 0000899243-22-025827 · doc4.xml · nonDerivative · entry 3 BELANOFF JOSEPH K · CIK 0001286199 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 01/29/02 Disclosed balance after: 2,538,218 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2022, as amended. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $26.21 to $26.65. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. F5 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 01/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 21:20 UTC |
BELANOFF JOSEPH KChief Executive Officer
|
Tax withholdingCommon Stock | 451,189 | $26.21 | $11,825,663.69 |
DisclosureSEC source: 0000899243-22-025827 · doc4.xml · nonDerivative · entry 2 BELANOFF JOSEPH K · CIK 0001286199 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,811 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and tax liability arising from a net (cashless) exercise of stock options that occurred on July 6, 2022. The options subject to the net exercise were to expire on January 30, 2023. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 21:20 UTC |
BELANOFF JOSEPH KChief Executive Officer
|
Exercise / conversionCommon Stock | 800,000 | $2.08 | $1,664,000.00 |
DisclosureSEC source: 0000899243-22-025827 · doc4.xml · nonDerivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 21:20 UTC |
Robb Gary CharlesChief Business Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 32,677 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-22-025826 · doc4.xml · derivative · entry 6 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,964 Underlying: Common Stock · 32,677 shares Expires 2023-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 21:20 UTC |
Robb Gary CharlesChief Business Officer
|
SaleCommon Stock | 45,000 | $26.00 | $1,170,000.00 |
DisclosureSEC source: 0000899243-22-025826 · doc4.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,123 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2022. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $26.00 to $26.001. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 21:20 UTC |
Robb Gary CharlesChief Business Officer
|
Exercise / conversionCommon Stock | 32,677 | $2.08 | $67,968.16 |
DisclosureSEC source: 0000899243-22-025826 · doc4.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,123 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2022 Filed Feb 14, 2025 21:40 UTC |
BELANOFF JOSEPH KDirector · Chief Executive Officer
|
OtherCommon Stock | 348,811 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-021329 · ownership.xml · nonDerivative · entry 2 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,831,918 F1 · kind: Transfer of shares without consideration to the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02. F2 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. F3 · ownership.nature: Due to an administrative error, prior reporting of the name of this trust has been corrected. The exact name of the trust, "Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02" was mistakenly identified as the "Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 01/29/02". Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.